Breaking News, Collaborations & Alliances

Abbisko, Merck Enter Licensing Agreement for Pimicotinib

Merck granted an exclusive option for global commercial rights of pimicotinib.

Abbisko Therapeutics has entered into a licensing agreement granting Merck an exclusive license to commercialize products comprising or containing pimicotinib (ABSK021) for all indications in Chinese mainland, Hong Kong, Macau, and Taiwan, and Abbisko Therapeutics retains exclusive rights to develop pimicotinib within the licensed territory. Abbisko Therapeutics has also granted Merck an exclusive option for global commercial rights of pimicotinib. Merck also has the option to co-de...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters